Harding Hospital
Columbus, Ohio, 43210, United States
Location status: Recruiting
NCT Number: NCT04368039
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Interested in participating?
Request Info15 year–35 year
All sexes
Interventional
Not applicable
Columbus, Ohio, 43210, United States
Location status: Recruiting
Functional deficits in prefrontal, limbic, and temporal regions of the brain are well-documented among individuals with psychotic disorders. Mitochondrial dysfunction may contribute to such pathology, and effective functioning of mitochondrial activity in the brain in dependent on a sufficient supply of oxygen. These data suggest that oxygen therapy may improve symptoms in individuals with psychosis. This small pilot study will test this hypothesis.
Individuals with first-episode psychosis will be randomized to receive either (i) 4 weeks of nightly normobaric oxygen therapy (40% FiO2) or (ii) 4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2). Participants will be blinded to what condition they receive. Both conditions will be delivered via nasal cannula connected to oxygen concentrators at five liters per minute (lpm), and participants will be instructed to complete the intervention overnight while sleeping. At the end of the 4 week period, all individuals will receive an additional 4 weeks of unblinded (i.e., "open label") nightly normobaric oxygen therapy (40% FiO2). Study assessments will be completed at (i) enrollment; (ii) 4 weeks after enrollment, and (iii) 8 weeks after enrollment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
40% FiO2 for 4 weeks
21% FiO2 for 4 weeks
Time frame: 4 weeks
Change in scores on the MATRICS Consensus Cognitive Battery (MCCB).
Time frame: 4 weeks
Change in scores on WHO Quality of Life Scale Brief (WHOQOL-BREF.
Time frame: 4 weeks
Change in scores on the Global Functioning: Social Scale. Scores on this measure range from 1-10 with higher scores indicating greater social functioning
Time frame: 4 weeks
Change in scores on the Global Functioning: Role Scale. Scores on this measure range from 1-10 with higher scores indicative of greater role functioning.
Time frame: 4 weeks
Change in scores on the RAND 36-Item Health Survey.
Time frame: 4 weeks
Change in occurrence in suicidal thoughts or behaviors as assessed using the Columbia Suicide Severity Rating Scale. This is a categorical rating scale that identifies the presence or absence of specific levels of severity of suicidal ideation and behavior.
Time frame: 4 weeks
Change in scores on the HABITS scale. This scale assesses the absolute values of use of specific substances (e.g., number of cigarettes smoked)
Time frame: 4 weeks
Change in scores on the Modified Service Use and Resources Form for Schizophrenia
Time frame: 4 weeks
Change in scores on the Pittsburgh Sleep Quality Index.
Time frame: 4 weeks
Change in scores on the Medication Adherence rating Scale. Scores on this scale range from 0-10 with higher scores indicative of greater medication adherence.
Contact information is provided by the study sponsor or research team.
Nicholas Breitborde
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04940663
Mental Disorders, Psychosis
Charlestown, Massachusetts, United States
View Trial DetailsNCT07196462
Cannabis Use, Mental Disorders
Nashville, Tennessee, United States
View Trial DetailsNCT06036316
At-risk Mental State, Communication Disorders
Laxou, France
View Trial DetailsNCT06107764
Bipolar Disorder I, Mental Disorders
Belmont, Massachusetts, United States
View Trial Details